



**NIDAN LABORATORIES
AND HEALTHCARE LTD**

ERSTWHILE NIDAN LABORATORIES & HEALTHCARE PVT LTD

CIN No. : U33111MH2000PLC129883

19.45707, 72.81031

Swagnashilp, Behind Aarti Apt. Vartak Road,
Virar (West), 401303, Mumbai, India.

Date: 13th November, 2021

To,
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex, Bandra (East),
Mumbai 400 051.

Subject: Outcome of the Board Meeting of Nidan Laboratories and Healthcare Limited held on Saturday, 13th November, 2021.

Reference: NSE Symbol: NIDAN

Madam / Sir,

This is to inform you that pursuant to Regulation 30 & Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") and other applicable provisions, the Board of Directors of the Company at its meeting held today have:

1. Approved the unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2021;
2. Taken on record the Limited Review Report issued by the Statutory Auditors of the Company for the aforesaid results;

In view of the above, we hereby enclose the following:

1. Un-audited Financial Results in respect of Nidan Laboratories and Healthcare Limited for quarter and half year ended 30th September, 2021.
2. Limited Review Report issued by Statutory Auditor's Report on the aforesaid financials quarter and half year ended 30th September, 2021.

The meeting of the Board of Directors of the Company commenced at 5.00 PM and concluded at 5.40 PM.

This is for your information and records.

For Nidan Laboratories and Healthcare Limited

Digitally signed
by Tejal Anil
Jayakar
Date: 2021.11.13
17:41:42 +05'30'

Tejal Anil Jayakar
Executive Director
DIN:07984686

NIDAN LABORATORIES AND HEALTHCARE LIMITED

CIN - U33111MH2000PLC129883

Regd Office: SY No. 294/A H. No. 18, Swapnshilpa, Behind Aarti Apartment,
Vartak Road, Virar (w), 401303

Tel No. +91 8975610000; E-Mail:cs@nidanhealthcare.co.in, Website: www.nidanhealthcare.co.in

Statement of Standalone Financial Results for the Quarter and Half year Ended on 30th September, 2021

	Particulars	Figures in Rupees -Lakhs	
		30-Sep-21	31-Mar-21
		Unaudited	Audited
1	Income		
	a) Revenue from Operations	1,652.21	2,079.19
	b) Other Income	1.23	106.13
	Total Income (a+b)	1,653.44	2,185.32
2	Expenses		
	a) Cost of Materials Consumed	201.54	222.94
	b) Purchase of Stock -in-trade	-	-
	c) Changes in inventories of Finished Goods, Work in Progress and Stock- in- Trade	(14.70)	(2.00)
	d) Employee benefit expenses	156.84	268.39
	e) Finance Costs	171.87	346.15
	f) Depreciation and Amortization expenses	175.94	318.44
	g) Other Expenses	729.22	701.17
	Total Expenses (a to g)	1,420.71	1,855.09
3	Profit / (Loss) before tax	232.73	330.23
4	Tax Expenses		
	a) Current Tax	52.36	99.99
	b) Deferred Tax Asset/Liability		
	Total tax expenses	52.36	99.99
5	Profit/(loss) for the period	180.37	230.24
6	Other Comprehensive Income (OCI)		
	A. (i) Items that will not be reclassified to profit or loss	-	-
	(ii) Income tax relating to Items that will not be reclassified to profit or loss	-	-
	B. (i) Items that will be reclassified to profit or loss	-	-
	(ii) Income tax relating to Items that will be reclassified to profit or loss	-	-
	Total other Comprehensive Income (Net of tax)	-	-
7	Total Comprehensive Income for the period	180.37	230.24
8	Paid-up equity share capital Face value of Rs 10/- per share	990.00	990.00
	Earnings Per Share (not annualised)		
9	a) Basic EPS	1.82	2.33
	b) Diluted EPS	1.82	2.33

Notes:

- 1) The Company does not have different segments and hence segment wise reporting is not applicable to the Company.
- 2) The above results have been approved by the Board of Directors in their meeting held on 13th November, 2021.
- 3) Previous year's figures have been regrouped / reclassified wherever necessary to correspond with the current year's classification / disclosure.
- 4) The above results have been prepared in accordance with the Company's {Indian Accounting Standards}, Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 5) The Statutory Auditor have been conducted limited Review of the above financial results.

For and on behalf of Board of Directors
NIDAN LABORATORIES AND HEALTHCARE LIMITED

Place : Virar
Date : 13th November, 2021

Tejal Anil Jayakar
Executive Director
DIN:07984686



NIDAN LABORATORIES AND HEALTHCARE LIMITED

CIN - U33111MH2000PLC129883

Regd Office: SY No. 294/A H. No. 18, Swapnshilpa, Behind Aarti Apartment,

Vartak Road, Virar (w), 401303

Tel No. +91 8975610000; E-Mail: cs@nidanhealthcare.co.in, Website: www.nidanhealthcare.co.in

Standalone statement of Assets and Liabilities as at 30.09.2021

Particulars	₹ in Lakh	₹ in Lakh
	As at 30th Sep, 2021	As at 31st March, 2021
	Unaudited	Audited
ASSETS		
Non-current assets		
Property, plant and equipment	2,083.92	2,014.16
Right of Use Assets		
Investment in Associates		
Financial assets		
- Investments	55.28	52.78
- Other financial assets	-	-
Other non current assets	25.07	25.07
Total non-current assets	2,164.27	2,092.01
Current assets		
Inventories	25.28	10.58
Financial assets		
- Investments	525.31	543.19
- Trade receivables	833.61	729.66
- Cash and cash equivalents	-	-
- Other financial assets	1,902.15	1,868.22
Other current assets		
Total current assets	3,286.35	3,151.65
TOTAL ASSETS	5,450.62	5,243.66
EQUITY AND LIABILITIES		
Equity		
Equity Share capital	990.00	990.00
Other equity	523.47	343.10
Total equity	1,513.47	1,333.10
Liabilities		
Non-current liabilities		
Financial liabilities		
- Borrowings	3,634.85	3,649.76
Other Financials liabilities	-	-
Provisions	-	-
Deferred tax liabilities (Net)		
Total non-current liabilities	3,634.85	3,649.76
Current liabilities		
Financial liabilities		
- Borrowings		
- Trade payables	141.49	152.37
Other Financials liabilities		
Other current liabilities	160.81	108.43
Total current liabilities	302.30	260.80
Total liabilities	5,450.62	5,243.66
TOTAL EQUITY AND LIABILITIES		

For and on behalf of Board of Directors
NIDAN LABORATORIES AND HEALTHCARE LIMITED

Tejal Anil Jayakar
Executive Director
DIN:07984686

Place : Virar

Date : 13th November, 2021

NIDAN LABORATORIES AND HEALTHCARE LIMITED

CIN - U33111MH2000PLC129883

Regd Office: SY No. 294/A H. No. 18, Swapnshilpa, Behind Aarti Apartment,
Vartak Road, Virar (w), 401303

Tel No. +91 8975610000; E-Mail:cs@nidanhealthcare.co.in, Website: www.nidanhealthcare.co.in

Standalone Cash Flow Statement for the Half year ended 30th September, 2021


Particulars	₹ in Lakh	₹ in Lakh
	Half year ended 30th Sep, 2021	year ended 31st March, 2021
	Unaudited	Audited
A. Cash flow from operating activities		
Net Profit / (Loss) before extraordinary items and tax		
<u>Adjustments for:</u>		
Depreciation and amortisation (Net of Depreciation Withdrawn)	232.74	330.23
Finance costs	175.94	318.44
Interest income	171.88	346.15
Short Term Capital Gain on Redemption of Mutual Funds	-	-
Mark to Market Transaction Gain	-	-
Profit on Sale of Assets	-	-
Exchange Fluctuation on Container Lease payments	-	-
Sundry balances written back	-	-
Gratuity Paid	-	-
Preliminary Expenses W/off	-	-
Operating profit / (loss) before working capital changes	-	-
<u>Changes in assets and liabilities</u>		
Inventories	580.56	994.82
Trade receivables	-14.70	-2.00
Other financial assets and other assets	17.89	-
Trade payables	-33.94	-724.54
Other financial liabilities, other liabilities and provisions	-10.88	170.62
	-	7.33
Direct Taxes Paid	-41.63	-548.59
Net cash flow from / (used in) operating activities (A)		
B. Cash Flow From Investing Activities	538.93	446.23
Purchase of property, plant and equipment and intangible assets		
Proceeds from disposal of property, plant and equipment and intangible assets	-245.70	-324.44
Interest Income		
Short Term Capital Gain on Redemption of Mutual Funds		
Investment in Subsidiaries		
Investment in Mutual Funds		
Net cash flow from / (used in) investing activities (B)		
C. Cash flow from financing activities	-245.70	-324.44
Payment of Container Lease Liability		
Net increase / (decrease) in current financial liabilities for borrowings		
Net increase / (decrease) in non current financial liabilities for borrowings		
Finance cost	-14.92	214.73
Net cash flow from / (used in) financing activities (C)	-171.88	-346.15
Net increase / (decrease) in Cash and cash equivalents (A+B+C)	-186.80	-131.42
Cash and cash equivalents at the Beginning of the year	107.42	-9.63
Cash and cash equivalents at the end of the year *	729.68	739.31
	837.10	729.68

* Comprises:

- (a) Cash on hand
- (b) Balances with banks
 - (i) In current accounts
 - (ii) In EEFC accounts
 - (iii) In deposit accounts with Banks

For and on behalf of Board of Directors
NIDAN LABORATORIES AND HEALTHCARE LIMITED

Tejal Anil Jayakar
Executive Director
DIN:07984686



Place : Virar
Date : 13th November, 2021



R. K. CHAPAWAT & CO.

CHARTERED ACCOUNTANTS

Office : 122, Shripal Shopping Center, Near Petrol Pump, Agashi Road, Virar (West) Dist - Palghar : 401303.

Contact : +91-9323791318 / 0250-2513406, **E-mail :** ravindra_chapawat@rediffmail.com


INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

To The Board of Directors

NIDAN LABORATORIES AND HEALTHCARE LIMITED

1. We have reviewed the accompanying statement of unaudited standalone financial results of **NIDAN LABORATORIES AND HEALTHCARE LIMITED** ("the Company"), for the Quarter and Six Months ended September 30, 2021 ("the Statement"), together with the relevant notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The Statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.



3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data, and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For R. K.Chapawat & Co.
Chartered Accountants
(Firm Registration No.101708W)



Ravindra Chapawat
Partner
(Membership No. 37720)



Place: Virar
Date: 13-11-2021

UDIN : **21037720AAAAJZ8628**